AnaptysBio Inc (ANAB)
25.06
-0.40
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
25.06
0.00 (0.00%)
After-Hours: 20:00
AnaptysBio Enterprise Value: 330.21M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 330.21M |
| May 16, 2024 | 341.14M |
| May 15, 2024 | 344.69M |
| May 14, 2024 | 335.40M |
| May 13, 2024 | 300.71M |
| May 10, 2024 | 284.86M |
| May 09, 2024 | 361.90M |
| May 08, 2024 | 348.79M |
| May 07, 2024 | 346.88M |
| May 06, 2024 | 349.34M |
| May 03, 2024 | 371.46M |
| May 02, 2024 | 364.91M |
| May 01, 2024 | 356.16M |
| April 30, 2024 | 310.27M |
| April 29, 2024 | 227.22M |
| April 26, 2024 | 219.03M |
| April 25, 2024 | 160.84M |
| April 24, 2024 | 171.76M |
| April 23, 2024 | 169.31M |
| April 22, 2024 | 182.42M |
| April 19, 2024 | 188.16M |
| April 18, 2024 | 187.06M |
| April 17, 2024 | 231.87M |
| April 16, 2024 | 228.31M |
| April 15, 2024 | 226.40M |
| Date | Value |
|---|---|
| April 12, 2024 | 265.70M |
| April 11, 2024 | 320.87M |
| April 10, 2024 | 250.94M |
| April 09, 2024 | 233.46M |
| April 08, 2024 | 209.97M |
| April 05, 2024 | 221.17M |
| April 04, 2024 | 227.18M |
| April 03, 2024 | 211.34M |
| April 02, 2024 | 214.61M |
| April 01, 2024 | 227.72M |
| March 31, 2024 | 260.51M |
| March 28, 2024 | 211.80M |
| March 27, 2024 | 181.29M |
| March 26, 2024 | 187.18M |
| March 25, 2024 | 173.80M |
| March 22, 2024 | 189.05M |
| March 21, 2024 | 263.45M |
| March 20, 2024 | 249.80M |
| March 19, 2024 | 231.87M |
| March 18, 2024 | 229.20M |
| March 15, 2024 | 236.69M |
| March 14, 2024 | 240.71M |
| March 13, 2024 | 269.88M |
| March 12, 2024 | 306.54M |
| March 11, 2024 | 234.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-141.71M
Minimum
Nov 08 2019
1.692B
Maximum
May 29 2019
281.43M
Average
239.37M
Median
Enterprise Value Benchmarks
| XOMA Corp | 280.98M |
| Fate Therapeutics Inc | 60.40M |
| Ocular Therapeutix Inc | 539.23M |
| Apellis Pharmaceuticals Inc | 4.781B |
| Sutro Biopharma Inc | 14.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.94M |
| Revenue (Quarterly) | 7.179M |
| Total Expenses (Quarterly) | 49.38M |
| EPS Diluted (Quarterly) | -1.64 |
| Profit Margin (Quarterly) | -612.0% |
| Earnings Yield | -24.49% |
| Normalized Earnings Yield | -24.49 |